Investing.com - Humanigen reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Humanigen announced earnings per share of $-0.2300 on revenue of $221.0K. Analysts polled by Investing.com anticipated EPS of $-0.1805 on revenue of $260K.
Humanigen shares are down 95% from the beginning of the year , still down 97.59% from its 52 week high of $6.95 set on Wednesday, November 17, 2021.
Humanigen follows other major Healthcare sector earnings this month
Humanigen's report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
Pfizer had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.78 on revenue of $22.6B, compared to forecast for EPS of $1.44 on revenue of $21.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar